These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 11008124)

  • 1. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.
    Ferry KV; Hamilton TC; Johnson SW
    Biochem Pharmacol; 2000 Nov; 60(9):1305-13. PubMed ID: 11008124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
    Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
    Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
    Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
    Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
    Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
    McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
    DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
    Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
    DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
    Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
    DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
    Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MZF1 possesses a repressively regulatory function in ERCC1 expression.
    Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
    Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
    Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
    Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of DNA repair gene expression in human cancer cell lines.
    McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
    J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.
    Yu JJ; Bicher A; Ma YK; Bostick-Bruton F; Reed E
    Cancer Lett; 2000 Apr; 151(2):127-32. PubMed ID: 10738106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
    Du P; Zhang X; Liu H; Chen L
    DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
    De Silva IU; McHugh PJ; Clingen PH; Hartley JA
    Nucleic Acids Res; 2002 Sep; 30(17):3848-56. PubMed ID: 12202770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
    Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
    Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells.
    Sun Y; Li T; Ma K; Tian Z; Zhu Y; Chen F; Hu G
    Cancer Invest; 2009 Nov; 27(9):891-7. PubMed ID: 19832035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.